Compaison of efficacy and safety of different routes of administration of tirofiban in the treatment of coronary heart disease complicated with acute myocardial infarction
Objective To investigate the efficacy and safety of different routes of administration of tirofiban in the treatment of coronary heart disease complicated with acute myocardial infarction.Methods A total of 124 patients with coronary heart disease complicated with acute myocardial infarction admitted from January 2019 to February 2022 were selected and divided into control group and observation group according to the mode of administration,with 62 cases in each group.The control group was treated with tirofiban by intravenous injection,and the observation group was treated with tirofiban by coronary artery injection.The therapeutic effects of the two groups were compared.Results After treatment,the coronary flow velocity reserve(CFVR),diastolic peak velocity(DPV)and systolic peak velocity(SPV)in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of lactate dehydrogenase(LDH),creatine kinase isoenzyme(CK-MB),cardiac troponin I(cTnI)and myoglobin(MYO)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the proportion of thrombolysis in myocardial infarction(TIMI)grade Ⅱ in the observation group was significantly lower than that in the control group,the proportion of grade Ⅲ was significantly higher than that in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse events in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Tirofiban administrated by coronary artery injection in the treatment of coronary heart disease complicated with acute myocardial infarction can further regulate the coronary blood flow and levels of myocardial enzymes,improve TIMI classification and reduce the incidence of adverse events.
tirofibancoronary heart diseaseacute myocardial infarctiondifferent routes of administrationcoronary blood flow
万方数据
维普
